In its place, the PBM included the Humira-referenced biosimilars Hyrimoz, Hadlima and adalimumab-fkjp (an unbranded product). Hyrimoz appears to be the most favored biosimilar. While removal of ...

The South Korean drugmaker added that Hyrimoz and Hadlima, Humira biosimilars marketed by CVS Health (CVS)/Sandoz (SDXNY) (OTCQX:SDZXF) and Organon (OGN)/Samsung Bioepis, respectively, have led to ...